CL2004000391A1 - Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina. - Google Patents

Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Info

Publication number: CL2004000391A1
Authority: CL; Chile
Prior art keywords: compounds; dislipidemia; oxazol; diabetes; pharmaceutical composition
Prior art date: 2003-02-27

Application number

CL200400391A

Other languages

English (en)

Inventor

Kirk Glombik Heiner Fa Gretzke

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-27

Publication date

2005-01-07

2004-02-27 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2005-01-07 Publication of CL2004000391A1 publication Critical patent/CL2004000391A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

CL200400391A 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina. CL2004000391A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
CL2004000391A1 true CL2004000391A1 (es)	2005-01-07

Family

ID=32920629

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL200400392A CL2004000392A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
CL200400391A CL2004000391A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL200400392A CL2004000392A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Country Status (34)

Country	Link
US (5)	US7259177B2 (es)
EP (3)	EP1599452B1 (es)
JP (3)	JP2006519193A (es)
KR (3)	KR20050106461A (es)
CN (3)	CN100439347C (es)
AR (3)	AR043433A1 (es)
AT (3)	ATE430738T1 (es)
AU (3)	AU2004215672B2 (es)
BR (3)	BRPI0407814A (es)
CA (3)	CA2517381A1 (es)
CL (2)	CL2004000392A1 (es)
CO (2)	CO5690580A2 (es)
DE (4)	DE10308355A1 (es)
DK (3)	DK1599453T3 (es)
EC (2)	ECSP055986A (es)
ES (3)	ES2329366T3 (es)
HR (3)	HRP20050742A2 (es)
IL (2)	IL170314A (es)
MA (3)	MA27736A1 (es)
MX (3)	MXPA05008995A (es)
NO (3)	NO20054398L (es)
OA (2)	OA13034A (es)
PA (1)	PA8596801A1 (es)
PE (3)	PE20050292A1 (es)
PL (3)	PL378437A1 (es)
PT (3)	PT1599453E (es)
RS (1)	RS20050594A (es)
RU (3)	RU2005129995A (es)
SA (1)	SA04250153A (es)
TN (2)	TNSN05204A1 (es)
TW (3)	TW200500349A (es)
UY (2)	UY28209A1 (es)
WO (3)	WO2004076426A1 (es)
ZA (2)	ZA200505768B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en)	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de)	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) *	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
AU2006299091A1 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
KR101398715B1 (ko)	2006-08-10	2014-05-27	가부시키가이샤 미모잭스	아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
JP5340287B2 (ja)	2007-08-16	2013-11-13	ソルヴェイ（ソシエテアノニム）	４−フルオロ置換３−オキソ−アルカン酸のエステル類の調製方法
TWI476187B (zh) *	2008-02-29	2015-03-11	Nissan Chemical Ind Ltd	Thiophene compounds and intermediates thereof
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
EP4050422B1 (en)	2017-12-13	2024-11-20	Canon Kabushiki Kaisha	Cartridge and image forming apparatus
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr)	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997026265A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
EP1826216A1 (en)	1996-08-30	2007-08-29	Novo Nordisk A/S	Glp-1 derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
ATE246190T1 (de)	1996-12-31	2003-08-15	Reddys Lab Ltd Dr	Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt)	1997-07-16	2000-09-12	Novo Nordisk As	Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) *	1998-03-10	2003-01-14	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) *	1998-08-27	2003-12-16	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de)	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en)	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
JP2002542245A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	置換イミダゾール、それらの製造および使用
KR100693771B1 (ko) *	1999-04-28	2007-03-12	사노피-아벤티스 도이칠란트 게엠베하	Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CN1331862C (zh)	1999-04-28	2007-08-15	萨诺费－阿文蒂斯德国有限公司	作为ppar受体配体的二芳基酸衍生物
JP2002543200A (ja)	1999-04-30	2002-12-17	ニューロゲンコーポレイション	９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
EP1194146B1 (en)	1999-06-18	2006-07-19	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en)	1999-07-09	2002-07-02	Cohesion Technologies, Inc.	Ecarin prothrombin protease and methods
WO2001009111A1 (en)	1999-07-29	2001-02-08	Eli Lilly And Company	Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
SK2682002A3 (en) *	1999-09-01	2002-07-02	Aventis Pharma Gmbh	Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TW200514783A (en)	1999-09-22	2005-05-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
WO2001040171A1 (en)	1999-12-03	2001-06-07	Astrazeneca Ab	Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
WO2001072290A2 (en)	2000-03-31	2001-10-04	Probiodrug Ag	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
WO2001081327A1 (en)	2000-04-25	2001-11-01	Kyorin Pharmaceutical Co., Ltd.	Novel stable crystal of thiazolidinedione derivative and process for producing the same
AU5257401A (en)	2000-04-28	2001-11-12	Asahi Chemical Ind	Novel bicyclic compounds
EP1280777B1 (en)	2000-05-11	2005-11-23	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU6497701A (en)	2000-05-30	2001-12-11	Merck & Co Inc	Melanocortin receptor agonists
TR200401029T4 (tr)	2000-06-09	2004-06-21	Aventis Pharma Deutschland Gmbh	Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
NZ523804A (en) *	2000-08-23	2004-09-24	Lilly Co Eli	Peroxisome proliferator activated receptor agonists
ATE368653T1 (de)	2000-08-23	2007-08-15	Lilly Co Eli	Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja)	2000-12-05	2004-04-08	杏林製薬株式会社	置換カルボン酸誘導体
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
CN1217927C (zh)	2000-12-21	2005-09-07	阿文蒂斯药物德国有限公司	新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
CN100357280C (zh) *	2000-12-25	2007-12-26	小野药品工业株式会社	二氢化萘衍生物及包含该衍生物作为活性成分的药物
CA2438551A1 (en)	2001-02-15	2002-08-22	Pfizer Products Inc.	Ppar agonists
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
IL159002A0 (en) *	2001-06-07	2004-05-12	Lilly Co Eli	Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003005025A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
ATE347890T1 (de)	2001-08-31	2007-01-15	Sanofi Aventis Deutschland	Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren
WO2003066581A1 (en)	2002-02-05	2003-08-14	Eli Lilly And Company	Urea linker derivatives for use as ppar modulators
IL164249A0 (en)	2002-04-11	2005-12-18	Aventis Pharma Gmbh	Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en)	2002-07-09	2004-01-15	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de not_active Ceased
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Ceased
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Ceased
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Ceased
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de not_active Ceased
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de not_active Ceased
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en not_active Expired - Lifetime
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en not_active Expired - Lifetime
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO20054396L (no)	2005-11-11
EP1599455A1 (de)	2005-11-30
WO2004076426A1 (de)	2004-09-10
CL2004000392A1 (es)	2005-04-22
AU2004215677B2 (en)	2010-01-07
MXPA05008988A (es)	2005-10-18
DE502004009690D1 (de)	2009-08-13
US7872034B2 (en)	2011-01-18
AR043433A1 (es)	2005-07-27
RU2005129992A (ru)	2006-02-10
WO2004076427A1 (de)	2004-09-10
TNSN05206A1 (en)	2007-06-11
BRPI0407907A (pt)	2006-02-14
RU2005129995A (ru)	2006-01-27
PL378130A1 (pl)	2006-03-06
UY28210A1 (es)	2004-09-30
DK1599452T3 (da)	2007-10-01
CN1753879A (zh)	2006-03-29
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
KR20050106462A (ko)	2005-11-09
JP2006519194A (ja)	2006-08-24
OA13034A (en)	2006-11-10
PE20040959A1 (es)	2005-01-17
AU2004215677A1 (en)	2004-09-10
PL378437A1 (pl)	2006-04-03
ES2329366T3 (es)	2009-11-25
DE502004004139D1 (de)	2007-08-02
WO2004076428A1 (de)	2004-09-10
US20080167354A1 (en)	2008-07-10
UY28209A1 (es)	2004-09-30
PL377735A1 (pl)	2006-02-20
PE20050292A1 (es)	2005-05-24
ES2287700T3 (es)	2007-12-16
US7259177B2 (en)	2007-08-21
ATE435217T1 (de)	2009-07-15
ECSP055985A (es)	2006-01-16
RU2005130002A (ru)	2006-01-27
CA2517386A1 (en)	2004-09-10
ATE430738T1 (de)	2009-05-15
CA2517381A1 (en)	2004-09-10
AU2004215672B2 (en)	2010-01-07
US20050101637A1 (en)	2005-05-12
TNSN05204A1 (en)	2007-06-11
SA04250153A (ar)	2005-12-03
HRP20050744A2 (en)	2006-09-30
US7335671B2 (en)	2008-02-26
US7365084B2 (en)	2008-04-29
CO5690578A2 (es)	2006-10-31
MA27737A1 (fr)	2006-02-01
CO5690580A2 (es)	2006-10-31
CN1753881A (zh)	2006-03-29
CN100439345C (zh)	2008-12-03
ES2326418T3 (es)	2009-10-09
KR20050106461A (ko)	2005-11-09
JP2006519193A (ja)	2006-08-24
DE10308355A1 (de)	2004-12-23
TW200510352A (en)	2005-03-16
PT1599452E (pt)	2007-09-12
AR043432A1 (es)	2005-07-27
ATE365159T1 (de)	2007-07-15
EP1599452B1 (de)	2007-06-20
EP1599455B1 (de)	2009-07-01
NO20054398L (no)	2005-11-02
HRP20050742A2 (en)	2006-09-30
EP1599453B1 (de)	2009-05-06
PT1599453E (pt)	2009-07-14
ECSP055986A (es)	2006-01-16
EP1599453A1 (de)	2005-11-30
US20040209920A1 (en)	2004-10-21
DK1599453T3 (da)	2009-08-24
MXPA05008951A (es)	2005-11-04
IL170314A (en)	2010-11-30
ZA200505768B (en)	2005-11-23
MA27742A1 (fr)	2006-02-01
CA2516620A1 (en)	2004-09-10
JP2006519199A (ja)	2006-08-24
AU2004215672A1 (en)	2004-09-10
PT1599455E (pt)	2009-09-29
PE20050293A1 (es)	2005-05-24
CN100398526C (zh)	2008-07-02
AU2004215673B2 (en)	2009-10-01
TW200508210A (en)	2005-03-01
TW200500349A (en)	2005-01-01
EP1599452A1 (de)	2005-11-30
AU2004215673A1 (en)	2004-09-10
MXPA05008995A (es)	2005-10-18
DE502004009453D1 (de)	2009-06-18
MA27736A1 (fr)	2006-02-01
CN1756748A (zh)	2006-04-05
OA13035A (en)	2006-11-10
US20080015238A1 (en)	2008-01-17
BRPI0407758A (pt)	2006-02-14
ZA200505765B (en)	2006-05-31
NO20054396D0 (no)	2005-09-22
CN100439347C (zh)	2008-12-03
BRPI0407814A (pt)	2006-02-14
NO20054398D0 (no)	2005-09-22
AR043427A1 (es)	2005-07-27
KR20050105492A (ko)	2005-11-04
US20050215596A1 (en)	2005-09-29
RS20050594A (sr)	2007-12-31
NO20054408D0 (no)	2005-09-22
DK1599455T3 (da)	2009-11-09
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16

Publication	Publication Date	Title
CL2004000391A1 (es)	2005-01-07	Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
CL2007003440A1 (es)	2008-04-04	Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2004001069A1 (es)	2005-04-01	Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BRPI0311275A2 (pt)	2016-06-28	"composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
CL2007001918A1 (es)	2008-03-28	Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2011000144A1 (es)	2011-09-23	Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
CL2007003262A1 (es)	2008-05-30	Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
PL1730131T3 (pl)	2012-10-31	Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
CL2009000173A1 (es)	2010-02-12	Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2008002227A1 (es)	2009-04-17	Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
CL2004000827A1 (es)	2005-03-04	Compuestos derivados de 1,2-diazoles o 1,3-diazoles condensados con un heterociclo, composicion farmaceutica; y uso para tratar enfermedades moduladas por antagonistas de receptores canabinoides, tales como obesidad y sobrepeso.
CL2008001612A1 (es)	2009-05-15	5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
CL2007003264A1 (es)	2008-05-16	Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007003827A1 (es)	2008-09-26	Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CL2008001813A1 (es)	2008-08-22	Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
CL2007003263A1 (es)	2008-05-30	Compuestos derivados de 1,4-benzotiepina 1,1-dioxido; producto farmaceutico; procedimiento de preparacion; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, e
CR20110042A (es)	2011-07-06	Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo [1,4]dioxin-2-ilmetil)-sulfamida
CL2009000980A1 (es)	2009-08-14	Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
CL2007002970A1 (es)	2008-05-30	Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
DE602004017463D1 (de)	2008-12-11	Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
CL2007002196A1 (es)	2008-05-30	Compuestos heterociclicos nitrogenados, moduladores de la actividad del receptor de quimioquina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, obesidad, sindrome metabolico y dolor.
CL2007002511A1 (es)	2008-05-16	Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune.
DE602006020273D1 (de)	2011-04-07	Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon